glp-1 gi obstruction class action in kentucky digestive blockage Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal kentucky glp-1 gastrointestinal obstruction class

Only recently have they been shown to be effective in treating obesity.

Childhood obesity rates have skyrocketed over 300% since the 1970s, now affecting 21% of children

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels